Principal Financial Group Inc. Takes $35,000 Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Principal Financial Group Inc. bought a new position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,006 shares of the company’s stock, valued at approximately $35,000.

A number of other institutional investors also recently added to or reduced their stakes in PSTX. Dynamic Technology Lab Private Ltd acquired a new position in shares of Poseida Therapeutics during the fourth quarter worth $36,000. Cantor Fitzgerald L. P. purchased a new stake in Poseida Therapeutics in the fourth quarter valued at about $169,000. Russell Investments Group Ltd. purchased a new stake in Poseida Therapeutics in the first quarter valued at about $110,000. Blair William & Co. IL boosted its holdings in Poseida Therapeutics by 41.3% in the first quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock worth $3,079,000 after acquiring an additional 282,310 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after acquiring an additional 473,746 shares during the last quarter. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Stock Down 2.3 %

Shares of PSTX opened at $3.00 on Tuesday. The stock has a 50 day moving average price of $3.09 and a 200 day moving average price of $2.95. Poseida Therapeutics, Inc. has a one year low of $1.83 and a one year high of $4.27. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.48 and a current ratio of 2.48. The stock has a market capitalization of $291.39 million, a price-to-earnings ratio of -2.52 and a beta of 0.51.

Poseida Therapeutics (NASDAQ:PSTX) last released its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. The business had revenue of $25.97 million for the quarter, compared to analyst estimates of $13.75 million. Equities research analysts forecast that Poseida Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Poseida Therapeutics in a research report on Tuesday, August 6th.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.